EGFR S768_D770dup

CI-VAR-00004122Explore in graph →CIViC 1511

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma2
EGFR S768_D770dup	Erlotinib	Predictive	C	Supports Resistance	—	submitted	EID4490 In a retrospective study of 46 Caucasian, advanced lung adenocarcinoma patients, a patient harboring EGFR S768_D770insSVD mutation was associated with resistance to erlotinib treatment. The patient su… (full text at CIViC) PMID 27032107 · De Grève et al., 2016 · Open in CIViC	civic
EGFR S768_D770dup	Paclitaxel + TislelizumabCombination	Predictive	C	Supports Sensitivity Response	2	submitted	EID13094 A 48-year-old man with stage IVB lung adenocarcinoma harboring an EGFR S768_D770dup exon 20 insertion and high PD-L1 expression (TPS 50%) received third-line paclitaxel plus tislelizumab after progres… (full text at CIViC) PMID 42558558 · Zhao et al., 2026 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Lung Non-Small Cell Carcinoma2
EGFR S768_D770dup	Osimertinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID9224 In a retrospective study of 2316 Chinese patients with stage IV non-small cell lung carcinoma, two patients with the EGFR exon 20 insertion S768_D770dup received osimertinib treatment. A 59 year old f… (full text at CIViC) PMID 31208370 · Fang et al., 2019 · Open in CIViC	civic
EGFR S768_D770dup OR EGFR A767_V769dupASV	Sunvozertinib	Predictive	A	Supports Sensitivity Response	4	accepted	EID12623 In a multinational open label phase II dose randomized study of sunvozertinib in platinum pretreated advanced NSCLC with EGFR exon 20 insertion mutations (WU-KONG1B, NCT03974022; efficacy n = 85 for 2… (full text at CIViC) PMID 40923280 · Yang et al., 2025 · Open in CIViC	civic